Observations placeholder
Nexavar
Identifier
019686
Type of Spiritual Experience
Background
A description of the experience
Sorafenibas Nexavar is a kinase inhibitor drug approved for the treatment of primary kidney cancer (advanced renal cell carcinoma), advanced primary liver cancer (hepatocellular carcinoma), and radioactive iodine resistant advanced thyroid carcinoma.
Adverse effects by frequency
Note: Potentially serious side effects are in bold.
Very common (>10% frequency)
- Lymphopenia
- Hypophosphataemia
- Haemorrhage
- Hypertension
- Diarrhea
- Rash
- Alopecia (hair loss; occurs in roughly 30% of patients receiving sorafenib)
- Hand-foot syndrome
- Pruritus (itchiness)
- Erythema
- Increased amylase
- Increased lipase
- Fatigue
- Pain
- Nausea
- Vomiting
Common (1-10% frequency)
- Leucopoenia
- Neutropoenia
- Anaemia,Thrombocytopenia
- Anorexia (weight loss)
- Hypocalcaemia
- Hypokalaemia
- Depression
- Peripheral sensory neuropathy
- Tinnitus
- Congestive heart failure
- Myocardial infarction,Myocardial ischaemia
- Hoarseness
- Constipation
- Stomatitis
- Dyspepsia
- Dysphagia
- Dry skin
- Exfoliative dermatitis
- Acne
- Skin desquamation
- Arthralgia
- Myalgia
- Renal failure
- Proteinuri
- Erectile dysfunction
- Asthenia (weakness)
- Fever
- Influenza-like illness
- Transient increase in transaminase
Uncommon (0.1-1% frequency)
- Folliculitis
- Infection
- Hypersensitivity reactions
- Hypothyroidism
- Hyperthyroidism
- Hyponatraemia
- Dehydration
- Reversible posterior leukoencephalopathy
- Hypertensive crisis
- Rhinorrhoea
- Interstitial lung disease-like event
- Gastro-oesophageal reflux disease (GORD)
- Pancreatiti
- Gastritis
- Gastrointestinal perforation
- Increase in bilirubin leading, potentially, to jaundice
- Cholecystitis
- Cholangitis
- Eczema
- Erythema multiforme
- Keratoacanthoma
- Squamous cell carcinoma
- Gynaecomastia (swelling of the breast tissue in men)
- Transient increase in blood alkaline phosphatase
- INR abnormal
- Prothrombin level abnormal
- bulbous skin reaction
Rare (0.01-0.1% frequency)
- QT interval prolongation
- Angiooedem
- Anaphylactic reaction
- Hepatitis
- Radiation recall dermatitis
- Stevens-Johnson syndrom
- Leucocytoclastic vasculitis
- Toxic epidermal necrolysis
- Nephrotic syndrome
- Rhabdomyolysis
On Dec, 24, 2016 16,152 people reported to have side effects when taking Nexavar.
Among them, 33 people (0.2%) have Hallucination
Time on Nexavar when people have Hallucination :
< 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
Hallucination | 76.19% | 23.81% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Gender of people who have Hallucination when taking Nexavar :
Female | Male | |
Hallucination | 14.29% | 85.71% |
Age of people who have Hallucination when taking Nexavar :
0-1 | 2-9 | 10-19 | 20-29 | 30-39 | 40-49 | 50-59 | 60+ | |
Hallucination | 0.00% | 0.00% | 0.00% | 0.00% | 2.50% | 2.50% | 30.00% | 65.00% |
On Jan, 21, 2016: 12,257 people reported to have side effects when taking Nexavar. Among them, 615 people (5.02%) have Death.
Time on Nexavar when people have Death :
< 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
Death | 53.33% | 36.97% | 4.24% | 5.45% | 0.00% | 0.00% | 0.00% |
Gender of people who have Death when taking Nexavar :
Female | Male | |
Death | 25.00% | 75.00% |
Age of people who have Death when taking Nexavar :
0-1 | 2-9 | 10-19 | 20-29 | 30-39 | 40-49 | 50-59 | 60+ | |
Death | 0.00% | 0.28% | 0.00% | 0.28% | 1.52% | 6.22% | 29.46% | 62.24% |